Ellen Wermter, FNP-BC, DBSM, FAASM

In the final episode, 'Multidisciplinary Approaches to Long-Term Narcolepsy Care,' the panelists explore the multidisciplinary challenges inherent in managing narcolepsy over the long term, opening with a candid discussion of how fragmented healthcare systems and limited communication infrastructure make true care coordination difficult. In practice, the burden of bridging different care teams often falls on the patient, with the expert panel encouraging patients to keep all providers informed of treatment changes to avoid conflicting approaches.

This episode, titled 'Optimizing Narcolepsy Treatment Through Polypharmacy,' features panelists discussing the role of polypharmacy in narcolepsy treatment, challenging the notion that a single agent is sufficient for most patients. While research suggests roughly 60% of narcolepsy patients are on multiple medications, the expert panel notes that in their own clinical practices the rate is considerably higher, reflecting a more aggressive pursuit of optimal outcomes. The anticipated arrival of orexin receptor agonists is acknowledged as potentially transformative, though the expert panel stops short of assuming any single agent will address the full spectrum of narcolepsy symptoms.

In 'Assessing DEA Scheduling and Emerging Therapies in Narcolepsy,' our panel delves into the practical implications of DEA scheduling on narcolepsy treatment decisions, noting that available medications span the scheduling spectrum from unscheduled agents like pitolisant to schedule three oxybates and schedule two stimulants.

In this episode, 'Narcolepsy Treatment Considerations in Pediatric Patients', the experts explore the pharmacologic treatment of narcolepsy in pediatric patients, beginning with a review of FDA-approved options for children. The expert panel notes that the oxybate class, including sodium oxybate, low-sodium oxybate, and once-nightly oxybate, carries approval for excessive daytime sleepiness and cataplexy in patients seven and older, while pitolisant is approved for ages six and up for both indications, including a recently added cataplexy indication. The expert panel clarifies that traditional stimulants and solriamfetol have not been specifically studied or approved for cataplexy treatment.

This episode, titled 'Evaluating Pitolisant and Other Pharmacologic Treatment Options for Narcolepsy,' features panelists discussing the goals of narcolepsy management broadly, stressing that successful therapy extends beyond reducing excessive daytime sleepiness to include addressing cataplexy, hypnagogic hallucinations, sleep paralysis, and the psychological, social, and occupational consequences of the disease.

In 'Navigating Diagnostic Challenges in Narcolepsy,' our panel delves into the practical challenges of diagnosing narcolepsy in clinical settings, opening with a discussion of supplementary tools such as actigraphy, sleep diaries, and standardized scales including the Pittsburgh Sleep Quality Index.

In this episode, 'Narcolepsy Comorbidities, Quality of Life, and Risk Factors', the experts explore the far-reaching impact of narcolepsy beyond sleepiness, examining how sleep-wake instability undermines the ability to reliably show up for work, school, and relationships, often resulting in incomplete education, job loss, and chronic feelings of inadequacy. The persistence of sleepiness, unlike the restorative relief healthy individuals experience after rest, distinguishes narcolepsy as a fundamentally different and more burdensome condition.

This episode, titled 'Identifying Narcolepsy in Psychiatric Populations,' features panelists discussing the challenges of recognizing narcolepsy in psychiatric populations, where overlapping symptoms of mood dysregulation, fatigue, and attention difficulties can easily redirect clinical attention away from an underlying sleep disorder.

In 'Reviewing the Prevalence and Underdiagnosis of Narcolepsy,' our panel delves into the prevalence and underdiagnosis of narcolepsy, pushing back against the widespread assumption that it is a rare condition.

In this episode, 'Recognizing Narcolepsy Across the Lifespan', the experts explore the clinical presentation of narcolepsy, beginning with the one symptom universal to all patients: excessive daytime sleepiness. The expert panel notes that sleepiness can manifest differently across individuals, with some patients actively masking it through compensatory behaviors, making it easy to underestimate or overlook.

Welcome back to another Neurology Times Peer Exchange series. In this episode titled, 'Understanding Narcolepsy as More Than a Sleep Disorder', the moderator, Dr. Karl Doghramji, led the conversation about excessive daytime sleepiness as a widespread clinical challenge, with the expert panel narrowing the focus to narcolepsy, a central disorder of hypersomnolence that is frequently missed in practice.